Regen Biopharma INC
Market Movers (8-K)
OID
Regen Biopharma Inc. announced a settlement agreement resolving a lawsuit for $398,740 and the appointment of a new independent registered public accounting firm.
Capital raise
OID
REGEN BIOPHARMA, INC. issued 77.8 million common shares to satisfy convertible debt principal, accrued interest, and incurred fees.
Worse than expected
Capital raise
OID
REGEN BIOPHARMA, INC. announced the issuance of over 21 million common shares to satisfy convertible debt and raise $50,000 in cash.
Capital raise
Worse than expected
OID
Regen Biopharma, Inc. announced a dividend payable in Series A Preferred Stock to shareholders of record as of February 3, 2026.
OID
REGEN BIOPHARMA, INC. announced the issuance of 23.68 million common shares across multiple transactions in October and November 2025, raising $191,800 in cash and converting $43,740 of debt.
Capital raise
OID
Regen Biopharma, Inc. is advancing its HemaXellerate therapy into a Phase I clinical trial, compensating key personnel with 40 million newly issued common shares.
Capital raise
Quarterly Earnings (10-Q)
OID
Regen Biopharma reported a net profit of $991,927 for Q2 2026, a significant turnaround from a net loss of $19,354 in the prior year, largely driven by derivative income.
Capital raise
OID
Regen Biopharma reported a significant increase in net loss and a critically low cash balance, raising substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
OID
Regen Biopharma, Inc. reported a significant increase in net loss for the nine months ended June 30, 2025, and disclosed substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
OID
Regen Biopharma, an early-stage biopharmaceutical company, reported a significantly increased net loss and critically low cash balance for the six months ended March 31, 2025, leading to substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
OID
Regen Biopharma's Q1 2025 results show an increased net loss primarily due to derivative losses, despite a reduction in operating expenses.
Capital raise
Worse than expected
OID
10-Q: Regen BioPharma Reports Q3 2024 Results, Cites Ongoing Losses and Need for Additional Financing
Regen BioPharma's Q3 2024 report reveals continued operating losses and a reliance on equity financing, highlighting the company's ongoing need for capital.
Worse than expected
Capital raise
Annual Reports (10-K)
OID
Regen Biopharma, Inc. filed its annual 10-K, revealing a significant increase in net loss to $1.27 million and substantial doubt about its ability to continue as a going concern, despite reduced operating cash burn.
Delay expected
Capital raise
Worse than expected
OID
Regen Biopharma's 10-K filing reveals continued focus on regenerative medicine applications, with ongoing research and development efforts and reliance on related party transactions for revenue and financing.
Capital raise
Worse than expected
Schedule 13G - Passive Investments
OID
Quick Capital, LLC has reported a 9.9% beneficial ownership stake in Regen BioPharma, Inc.'s common stock, holding 3,320,000 shares.